Sermorelin

Sermorelin

$75.00 – $120.00

Sermorelin is a synthetic peptide used in research to stimulate the release of growth hormone (GH) from the pituitary gland by mimicking the natural growth hormone-releasing hormone (GHRH). It is commonly studied in the context of GH secretion regulation and the impact of GH on growth, metabolism, and cellular function.

Research has shown that Sermorelin plays a pivotal role in stimulating the hypothalamus-pituitary axis, enhancing the release of endogenous GH. This peptide is also frequently used in studies focusing on aging, metabolic disorders, and muscle regeneration due to its influence on cellular regeneration and growth factor production.

This 10mg Sermorelin product is manufactured to research-grade standards, ensuring the peptide is pure and suitable for high-quality scientific investigations. It is intended for in vitro or in vivo use to investigate the mechanisms of GH release, metabolism, and related hormonal feedback loops, without any intention for clinical application in humans or animals.

0% 1 - 4 $75.00
10% 5 - 9 $67.50
20% 10 + $60.00
  • Free shipping on orders over $200
  • Discounts: Calculated in cart.

Description

Sermorelin is a synthetic peptide composed of 29 amino acids that functions as a growth hormone-releasing hormone (GHRH) analogue. By mimicking the natural GHRH, it stimulates the anterior pituitary to release growth hormone (GH) in a controlled manner. It acts on the GHRH receptor in the pituitary, prompting the secretion of GH, which then triggers downstream effects such as the stimulation of insulin-like growth factor 1 (IGF-1), a hormone that plays a central role in cell growth, muscle regeneration, and metabolic processes.

In research settings, Sermorelin has been utilized to investigate the physiological role of GH in growth, tissue repair, and metabolic function. Its impact on the hypothalamic-pituitary axis (HPA) has made it a valuable tool for studying pituitary regulation, feedback mechanisms, and hormone secretion dynamics. Because Sermorelin stimulates endogenous GH release, it serves as a useful agent for understanding how the body naturally controls growth hormone levels in response to various stimuli.

Sermorelin’s potential applications in the field of aging have also been a major research focus. As natural GH secretion declines with age, studies have explored how Sermorelin administration might restore GH levels and, by extension, counteract age-related declines in muscle mass, bone density, and metabolic rate. These studies suggest that Sermorelin may have promise in research related to age-associated decline in growth hormone production, offering a window into possible therapeutic strategies for combating aspects of aging at the cellular and metabolic levels.

Furthermore, Sermorelin has been employed in metabolic and obesity research to examine its role in regulating fat storage, insulin sensitivity, and lean muscle mass. It has been studied in animal models to investigate its effects on nutrient partitioning, as well as how it may influence energy homeostasis. Its impact on muscle regeneration has also drawn interest in the context of sports science and cellular repair.

Sermorelin is delivered in a lyophilized form to ensure maximum stability and purity. Researchers reconstitute it with appropriate solvents before using it in controlled studies, whether in cell cultures or animal models. The product is rigorously tested to ensure it meets high standards of purity and consistency, suitable for research applications requiring exacting scientific protocols.

Note: This product is intended strictly for laboratory research purposes. It is not approved for use in humans or animals.

Research

Sermorelin has been a significant subject of research due to its role in growth hormone (GH) stimulation. As a synthetic analogue of GHRH, it directly influences the release of GH from the pituitary gland, making it a valuable tool for studying GH dynamics and its downstream effects. The release of GH, in turn, has extensive implications for metabolic processes, tissue growth, and cellular repair.

In studies focused on aging, Sermorelin has been explored for its potential to combat the age-related decline in GH levels. As GH is a key factor in maintaining muscle mass, bone density, and metabolic health, its decline with age is often linked to several age-related conditions. Researchers have examined the potential of Sermorelin to mitigate these effects by stimulating the natural release of GH in older populations or in animal models of aging. This research is crucial for developing strategies to counteract the metabolic and regenerative declines associated with aging.

In the field of obesity and metabolic diseases, Sermorelin has been used to explore its effects on fat storage, lean body mass, and insulin sensitivity. Preclinical studies have indicated that Sermorelin may promote fat loss by enhancing the body’s ability to partition nutrients and increase the rate of fat oxidation, while also supporting the development of lean muscle tissue. This makes Sermorelin a promising agent for examining energy balance in metabolic disorders like obesity and diabetes.

Additionally, Sermorelin has been studied in the context of muscle regeneration and sports science. Due to its role in stimulating GH and IGF-1 production, it has been tested for its potential to accelerate muscle repair following injury or strenuous physical activity. Research has shown that these growth factors play a significant role in cellular regeneration, particularly in skeletal muscle cells.

Sermorelin has also been investigated for its ability to influence hormonal feedback loops. Its impact on the hypothalamic-pituitary-gonadal axis and the hypothalamic-pituitary-adrenal axis has provided insights into how the body maintains hormonal balance in response to various stressors, nutritional cues, and physical activity.

Through these extensive research applications, Sermorelin continues to offer valuable insights into the role of growth hormone in human physiology, aging, and disease. As a research tool, it holds significant promise for advancing our understanding of hormonal regulation, metabolic health, and the aging process.

This product is for research use only. It is not approved for human or veterinary use.

References:

  1. L. L. Bagno et al., “Growth Hormone–Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy,” J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis., vol. 4, no. 4, Mar. 2015.
  2. R. M. Kanashiro-Takeuchi et al., “New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor,” Oncotarget, vol. 6, no. 12, pp. 9728–9739, Mar. 2015.
  3. S. Tang et al., “Interactions between GHRH and GABAARs in the brains of patients with epilepsy and in animal models of epilepsy,” Sci. Rep., vol. 7, Dec. 2017.
  4. B. S. Shepherd et al., “Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss),” Comp. Biochem. Physiol. A. Mol. Integr. Physiol., vol. 146, no. 3, pp. 390–399, Mar. 2007.
  5. R. F. Walker, “Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?,” Clin. Interv. Aging, vol. 1, no. 4, pp. 307–308, Dec. 2006.
  6. S. T. Wahid, P. Marbach, B. Stolz, M. Miller, R. A. James, and S. G. Ball, “Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues,” Eur. J. Endocrinol., vol. 146, no. 3, pp. 295–302, Mar. 2002.

Related products

Scroll to Top
0